Danny Burke, CEO of ecancer, shared on LinkedIn:
“Catch up on ecancer’s coverage of the ESMO Congress 2026 with almost 40 interviews with the leading experts.
Explore the latest research and what it could mean for clinical practice, including: Bishal Gyawali; congress highlights and analysis, Andrea Necchi, perioperative treatment in bladder cancer, Brian Slomovitz; pembrolizumab in endometrial cancer, Bertrand Tombal and colleagues; surgery in high-risk localised prostate cancer, Félix Guerrero-Ramos and colleagues; advances in bladder cancer, Jacob Sands; tarlatamab plus durvalumab in small cell lung cancer and Alberto Briganti; perioperative apalutamide in prostate cancer.
You can also read: 25 Posts Not to Miss from ESMO Congress 2026: Day 5
